Trial Profile
An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Bapotulimab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms KEYNOTE920
- Sponsors Bayer
- 10 May 2023 Planned primary completion date changed from 30 Oct 2023 to 16 Jun 2023.
- 12 Jan 2023 Planned End Date changed from 30 Oct 2025 to 31 May 2024.
- 12 Jan 2023 Status changed from recruiting to active, no longer recruiting.